UBS AM’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

UBS AM’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-41,067	Closed	-$1.97M	–	2593
2020 Q1	$1.97M	Sell	41,067 -159,993	-80%	-$7.44M	﹤0.01%	1415
2019 Q4	$9.44M	Sell	201,060 -113,397	-36%	-$5.01M	0.01%	963
2019 Q3	$7.44M	Sell	314,457 -3,853	-1%	-$114K	0.01%	1058
2019 Q2	$9.57M	Buy	318,310 +3,478	+1%	+$79.7K	0.01%	976
2019 Q1	$7.05M	Buy	+314,832	New	+$6.77M	0.01%	1035
2018 Q2	–	Sell	-20,300	Closed	-$108K	–	2820
2018 Q1	$108K	Buy	+20,300	New	+$145K	﹤0.01%	2452

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

UBS AM's RARX Position: Q2 2020 in Review

UBS AM sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 41,067 shares — an estimated $1.97M sold.

UBS AM first reported a position in RARX in Q1 2018 and held it in 6 quarters. The position peaked at $9.57M in Q2 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

UBS AM reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
UBS AM sold 41,067 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $1.97M.
UBS AM first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 6 quarters.
UBS AM's Ra Pharmaceuticals, Inc. Common Stock position peaked at $9.57M in Q2 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on UBS AM's 13F filing for Q2 2020, filed 14 Aug 2020.